HER2 is a well-recognized proto-oncogene in HBC, with prognostic and predictive value, and several target therapies against HER2 have improved overall survival in women with breast cancer, showing also promising results on feline cell line studies [23,33,45]. Here, ERBB2 is linked to breast carcinoma.